Table 1

Sickness impact scores at baseline and mean (SEM) changes between 12 weeks and baseline, and 24 weeks and 12 weeks

Dimension
 (range)		Cilazapril (n = 182)1-150Captopril (n = 87)1-150Placebo/cilazapril (n = 82)1-150
BaselineChange 12–0Change 24–12BaselineChange 12–0Change 24–12BaselineChange 12–0Change 24–12
Ambulation11.85−3.90−0.9313.87−4.14+0.2511.80−2.57−0.98
 (0–50)(0.67)(0.48)(1.01)(0.80)(1.01)(0.89)
Mobility 7.01−2.77−0.42 7.96−2.37+0.63 6.53−0.70−1.72
 (0–92)(0.84)(0.50)(1.13)(0.84)(1.22)(0.81)
Body care and movement 4.79−1.35−0.17 6.58−1.65−0.58 5.47−1.36−1.29
 (0–53)(0.40)(0.32)(0.55)(0.60)(0.80)(0.59)
Physical dimension 6.88−2.24−0.40 8.58−2.38−0.14 7.18−1.51−1.30
 (0–47)(0.44)(0.29)(0.59)(0.50)(0.72)(0.60)
Social interaction10.35−2.25−1.2312.15−1.860.6713.48−3.78−1.92
 (0–91)(0.68)(0.55)(1.12)(0.96)(1.29)(1.10)
Communication 4.14−1.29+0.27 4.74−1.37+0.22 4.09−1.02−0.61
 (0–62)(0.65)(0.41)(1.03)(0.85)(0.96)(0.42)
Alertness12.89−3.40+0.1218.81−6.61−1.6115.44−4.26−3.16
 (0–90)(1.09)(0.79)(1.83)(1.54)(1.94)(1.55)
Emotional 6.48−2.35−0.15 8.00−2.23+0.16 7.03−1.72−1.79
 (0–81)(0.81)(0.39)(1.10)(1.01)(1.34)(0.77)
Psychosocial dimension 8.95−2.32−0.4411.30−2.84−0.5310.73−2.94−1.90
 (0–63)(0.57)(0.37)(0.90)(0.87)(1.08)(0.81)
Sleep and rest12.65−1.98−1.3618.04−5.13+1.0014.02−4.13−1.05
 (0–88)(0.87)(0.78)(1.59)(1.50)(1.52)(1.07)
Eating 3.51−0.81−0.15 3.82−1.03+0.38 3.97−0.50−0.62
 (0–39)(0.32)(0.32)(0.50)(0.44)(0.50)(0.37)
Work16.65−1.49−0.3822.10−4.81+0.5215.86−3.88−0.07
 (0–87)(2.09)(2.01)(3.63)(2.99)(3.44)(3.15)
Home management14.39−3.34−0.3018.79−4.01−0.2414.03−2.49−1.45
 (0–87)(1.00)(0.83)(2.11)(1.39)(1.26)(1.55)
Recreation18.33−4.55−2.8920.23−4.87+0.0316.43−3.59−1.72
 (0–88)(1.11)(1.06)(2.00)(1.67)(1.51)(1.53)
Total 9.17−2.29−0.5411.57−2.93−0.16 9.88−2.37−1.42
 (0–48)(0.45)(0.28)(0.69)(0.60)(0.73)(0.57)

  • A high score indicates a poor QOL. Maximum score is 100, minimum 0.

  • ↵1-150 Number of patients providing information at both 0 and 12 weeks.